CompletedPhase 3

A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia

South Korea214 participantsStarted 2023-02-23

Plain-language summary

This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.

Who can participate

Age range19 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 19 to 80 years * Patients with hypertension and hyperlipidemias Exclusion Criteria: * Orthostatic hypotension * History of ventricular tachycardia, atrial fibrillation * Uncontrolled diabetes mellitus

What they're measuring

The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm

Timeframe: 8 weeks

The change of LDL-C based on baseline between treatment arm and control 2 arm

Timeframe: 8 weeks

Trial details

NCT IDNCT05643508

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-09-10

View on ClinicalTrials.gov More Hypertension trials